These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28587063)

  • 41. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
    Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
    Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progression of liver disease in children and adults with lysosomal acid lipase deficiency.
    Burton BK; Silliman N; Marulkar S
    Curr Med Res Opin; 2017 Jul; 33(7):1211-1214. PubMed ID: 28320214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group.
    Kohli R; Ratziu V; Fiel MI; Waldmann E; Wilson DP; Balwani M
    Mol Genet Metab; 2020 Feb; 129(2):59-66. PubMed ID: 31767214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?
    Köse E; Çağatay E; Yaraş T; Kısa PT; Güler S; Gülten ZA; Akarsu M; Oktay Y; Kayalı HA; Arslan N
    Turk J Med Sci; 2022 Aug; 52(4):1075-1084. PubMed ID: 36326406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2.
    Hamilton J; Jones I; Srivastava R; Galloway P
    Clin Chim Acta; 2012 Aug; 413(15-16):1207-10. PubMed ID: 22483793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies.
    Zhang H
    Curr Opin Lipidol; 2018 Jun; 29(3):218-223. PubMed ID: 29547398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet.
    Lopresti MW; Cui W; Abernathy BE; Fredrickson G; Barrow F; Desai AS; Revelo XS; Mashek DG
    J Lipid Res; 2021; 62():100133. PubMed ID: 34624333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression and functional characterization of human lysosomal acid lipase gene (LIPA) mutation responsible for cholesteryl ester storage disease (CESD) phenotype.
    Rajamohan F; Reyes AR; Ruangsiriluk W; Hoth LR; Han S; Caspers N; Tu M; Ward J; Kurumbail RG
    Protein Expr Purif; 2015 Jun; 110():22-9. PubMed ID: 25620107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
    Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
    J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
    Poinsot P; Collardeau Frachon S; Restier L; Sérusclat A; Di Filippo M; Charrière S; Moulin P; Lachaux A; Peretti N
    J Clin Lipidol; 2017; 11(1):167-177.e3. PubMed ID: 28391883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2.
    Lukacs Z; Barr M; Hamilton J
    Clin Chim Acta; 2017 Aug; 471():201-205. PubMed ID: 28532785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease.
    Kuloglu Z; Kansu A; Selbuz S; Kalaycı AG; Şahin G; Kirsaclioglu CT; Demirören K; Dalgıç B; Kasırga E; Önal Z; İşlek A;
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):371-376. PubMed ID: 30540705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation.
    Leopold C; Duta-Mare M; Sachdev V; Goeritzer M; Maresch LK; Kolb D; Reicher H; Wagner B; Stojakovic T; Ruelicke T; Haemmerle G; Hoefler G; Sattler W; Kratky D
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Apr; 1864(4):500-511. PubMed ID: 30639734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.